ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Somatostatin Analogue Drug Market Research Report 2025
Published Date: July 2025
|
Report Code: QYRE-Auto-5F9122
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Somatostatin Analogue Drug Market Research Report 2022
BUY CHAPTERS

Global Somatostatin Analogue Drug Market Research Report 2025

Code: QYRE-Auto-5F9122
Report
July 2025
Pages:92
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Camurus AB
Chiasma Inc
Ipsen Group
Boehringer Ingelheim International GmbH
Eli Lilly & Co
F Hoffmann La Roche Ltd
Novartis
Pfizer Inc
Tarveda Therapeutics Inc
Teva Pharmaceutical Industries Ltd

Somatostatin Analogue Drug Market Size

The global market for Somatostatin Analogue Drug was valued at US$ 6770 million in the year 2024 and is projected to reach a revised size of US$ 10660 million by 2031, growing at a CAGR of 6.8% during the forecast period.

Somatostatin Analogue Drug Market

Somatostatin Analogue Drug Market

Somatostatin analogues are drugs that stop your body from making too many hormones. Some neuroendocrine tumours (NETs) make large amounts of hormones that cause a group of symptoms called carcinoid syndrome. Somatostatin analogues are a possible treatment for people with carcinoid syndrome.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Somatostatin Analogue Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Somatostatin Analogue Drug.
The Somatostatin Analogue Drug market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Somatostatin Analogue Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Somatostatin Analogue Drug companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Somatostatin Analogue Drug Market Report

Report Metric Details
Report Name Somatostatin Analogue Drug Market
Accounted market size in year US$ 6770 million
Forecasted market size in 2031 US$ 10660 million
CAGR 6.8%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • Octreotide
  • Lanreotide
  • Pasireotide
Segment by Application
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Camurus AB, Chiasma, Ipsen Group, Boehringer Ingelheim International GmbH, Eli Lilly & Co., F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., Tarveda Therapeutics Inc., Teva Pharmaceutical Industries Ltd.
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Somatostatin Analogue Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Somatostatin Analogue Drug Market growing?

Ans: The Somatostatin Analogue Drug Market witnessing a CAGR of 6.8% during the forecast period 2025-2031.

What is the Somatostatin Analogue Drug Market size in 2031?

Ans: The Somatostatin Analogue Drug Market size in 2031 will be US$ 10660 million.

Who are the main players in the Somatostatin Analogue Drug Market report?

Ans: The main players in the Somatostatin Analogue Drug Market are Camurus AB, Chiasma, Ipsen Group, Boehringer Ingelheim International GmbH, Eli Lilly & Co., F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., Tarveda Therapeutics Inc., Teva Pharmaceutical Industries Ltd.

What are the Application segmentation covered in the Somatostatin Analogue Drug Market report?

Ans: The Applications covered in the Somatostatin Analogue Drug Market report are Acromegaly, Neuroendocrine Tumor (NET), Others

What are the Type segmentation covered in the Somatostatin Analogue Drug Market report?

Ans: The Types covered in the Somatostatin Analogue Drug Market report are Octreotide, Lanreotide, Pasireotide

Recommended Reports

Hormone & Endocrine Drugs

Anticancer & Oncology Drugs

Peptide & Specialty Drugs

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Somatostatin Analogue Drug Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Octreotide
1.2.3 Lanreotide
1.2.4 Pasireotide
1.2.5 Octreotide
1.2.6 Lanreotide
1.2.7 Pasireotide
1.3 Market by Application
1.3.1 Global Somatostatin Analogue Drug Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Acromegaly
1.3.3 Neuroendocrine Tumor (NET)
1.3.4 Others
1.3.5 Acromegaly
1.3.6 Neuroendocrine Tumor (NET)
1.3.7 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Somatostatin Analogue Drug Market Perspective (2020-2031)
2.2 Global Somatostatin Analogue Drug Growth Trends by Region
2.2.1 Global Somatostatin Analogue Drug Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Somatostatin Analogue Drug Historic Market Size by Region (2020-2025)
2.2.3 Somatostatin Analogue Drug Forecasted Market Size by Region (2026-2031)
2.3 Somatostatin Analogue Drug Market Dynamics
2.3.1 Somatostatin Analogue Drug Industry Trends
2.3.2 Somatostatin Analogue Drug Market Drivers
2.3.3 Somatostatin Analogue Drug Market Challenges
2.3.4 Somatostatin Analogue Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Somatostatin Analogue Drug Players by Revenue
3.1.1 Global Top Somatostatin Analogue Drug Players by Revenue (2020-2025)
3.1.2 Global Somatostatin Analogue Drug Revenue Market Share by Players (2020-2025)
3.2 Global Somatostatin Analogue Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Somatostatin Analogue Drug Revenue
3.4 Global Somatostatin Analogue Drug Market Concentration Ratio
3.4.1 Global Somatostatin Analogue Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Somatostatin Analogue Drug Revenue in 2024
3.5 Global Key Players of Somatostatin Analogue Drug Head office and Area Served
3.6 Global Key Players of Somatostatin Analogue Drug, Product and Application
3.7 Global Key Players of Somatostatin Analogue Drug, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Somatostatin Analogue Drug Breakdown Data by Type
4.1 Global Somatostatin Analogue Drug Historic Market Size by Type (2020-2025)
4.2 Global Somatostatin Analogue Drug Forecasted Market Size by Type (2026-2031)
5 Somatostatin Analogue Drug Breakdown Data by Application
5.1 Global Somatostatin Analogue Drug Historic Market Size by Application (2020-2025)
5.2 Global Somatostatin Analogue Drug Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Somatostatin Analogue Drug Market Size (2020-2031)
6.2 North America Somatostatin Analogue Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Somatostatin Analogue Drug Market Size by Country (2020-2025)
6.4 North America Somatostatin Analogue Drug Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Somatostatin Analogue Drug Market Size (2020-2031)
7.2 Europe Somatostatin Analogue Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Somatostatin Analogue Drug Market Size by Country (2020-2025)
7.4 Europe Somatostatin Analogue Drug Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Somatostatin Analogue Drug Market Size (2020-2031)
8.2 Asia-Pacific Somatostatin Analogue Drug Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Somatostatin Analogue Drug Market Size by Region (2020-2025)
8.4 Asia-Pacific Somatostatin Analogue Drug Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Somatostatin Analogue Drug Market Size (2020-2031)
9.2 Latin America Somatostatin Analogue Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Somatostatin Analogue Drug Market Size by Country (2020-2025)
9.4 Latin America Somatostatin Analogue Drug Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Somatostatin Analogue Drug Market Size (2020-2031)
10.2 Middle East & Africa Somatostatin Analogue Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Somatostatin Analogue Drug Market Size by Country (2020-2025)
10.4 Middle East & Africa Somatostatin Analogue Drug Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Camurus AB
11.1.1 Camurus AB Company Details
11.1.2 Camurus AB Business Overview
11.1.3 Camurus AB Somatostatin Analogue Drug Introduction
11.1.4 Camurus AB Revenue in Somatostatin Analogue Drug Business (2020-2025)
11.1.5 Camurus AB Recent Development
11.2 Chiasma
11.2.1 Chiasma Company Details
11.2.2 Chiasma Business Overview
11.2.3 Chiasma Somatostatin Analogue Drug Introduction
11.2.4 Chiasma Revenue in Somatostatin Analogue Drug Business (2020-2025)
11.2.5 Chiasma Recent Development
11.3 Ipsen Group
11.3.1 Ipsen Group Company Details
11.3.2 Ipsen Group Business Overview
11.3.3 Ipsen Group Somatostatin Analogue Drug Introduction
11.3.4 Ipsen Group Revenue in Somatostatin Analogue Drug Business (2020-2025)
11.3.5 Ipsen Group Recent Development
11.4 Boehringer Ingelheim International GmbH
11.4.1 Boehringer Ingelheim International GmbH Company Details
11.4.2 Boehringer Ingelheim International GmbH Business Overview
11.4.3 Boehringer Ingelheim International GmbH Somatostatin Analogue Drug Introduction
11.4.4 Boehringer Ingelheim International GmbH Revenue in Somatostatin Analogue Drug Business (2020-2025)
11.4.5 Boehringer Ingelheim International GmbH Recent Development
11.5 Eli Lilly & Co.
11.5.1 Eli Lilly & Co. Company Details
11.5.2 Eli Lilly & Co. Business Overview
11.5.3 Eli Lilly & Co. Somatostatin Analogue Drug Introduction
11.5.4 Eli Lilly & Co. Revenue in Somatostatin Analogue Drug Business (2020-2025)
11.5.5 Eli Lilly & Co. Recent Development
11.6 F. Hoffmann-La Roche Ltd.
11.6.1 F. Hoffmann-La Roche Ltd. Company Details
11.6.2 F. Hoffmann-La Roche Ltd. Business Overview
11.6.3 F. Hoffmann-La Roche Ltd. Somatostatin Analogue Drug Introduction
11.6.4 F. Hoffmann-La Roche Ltd. Revenue in Somatostatin Analogue Drug Business (2020-2025)
11.6.5 F. Hoffmann-La Roche Ltd. Recent Development
11.7 Novartis AG
11.7.1 Novartis AG Company Details
11.7.2 Novartis AG Business Overview
11.7.3 Novartis AG Somatostatin Analogue Drug Introduction
11.7.4 Novartis AG Revenue in Somatostatin Analogue Drug Business (2020-2025)
11.7.5 Novartis AG Recent Development
11.8 Pfizer Inc.
11.8.1 Pfizer Inc. Company Details
11.8.2 Pfizer Inc. Business Overview
11.8.3 Pfizer Inc. Somatostatin Analogue Drug Introduction
11.8.4 Pfizer Inc. Revenue in Somatostatin Analogue Drug Business (2020-2025)
11.8.5 Pfizer Inc. Recent Development
11.9 Tarveda Therapeutics Inc.
11.9.1 Tarveda Therapeutics Inc. Company Details
11.9.2 Tarveda Therapeutics Inc. Business Overview
11.9.3 Tarveda Therapeutics Inc. Somatostatin Analogue Drug Introduction
11.9.4 Tarveda Therapeutics Inc. Revenue in Somatostatin Analogue Drug Business (2020-2025)
11.9.5 Tarveda Therapeutics Inc. Recent Development
11.10 Teva Pharmaceutical Industries Ltd.
11.10.1 Teva Pharmaceutical Industries Ltd. Company Details
11.10.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.10.3 Teva Pharmaceutical Industries Ltd. Somatostatin Analogue Drug Introduction
11.10.4 Teva Pharmaceutical Industries Ltd. Revenue in Somatostatin Analogue Drug Business (2020-2025)
11.10.5 Teva Pharmaceutical Industries Ltd. Recent Development
11.11 Camurus AB
11.11.1 Camurus AB Company Details
11.11.2 Camurus AB Business Overview
11.11.3 Camurus AB Somatostatin Analogue Drug Introduction
11.11.4 Camurus AB Revenue in Somatostatin Analogue Drug Business (2020-2025)
11.11.5 Camurus AB Recent Development
11.12 Chiasma
11.12.1 Chiasma Company Details
11.12.2 Chiasma Business Overview
11.12.3 Chiasma Somatostatin Analogue Drug Introduction
11.12.4 Chiasma Revenue in Somatostatin Analogue Drug Business (2020-2025)
11.12.5 Chiasma Recent Development
11.13 Ipsen Group
11.13.1 Ipsen Group Company Details
11.13.2 Ipsen Group Business Overview
11.13.3 Ipsen Group Somatostatin Analogue Drug Introduction
11.13.4 Ipsen Group Revenue in Somatostatin Analogue Drug Business (2020-2025)
11.13.5 Ipsen Group Recent Development
11.14 Boehringer Ingelheim International GmbH
11.14.1 Boehringer Ingelheim International GmbH Company Details
11.14.2 Boehringer Ingelheim International GmbH Business Overview
11.14.3 Boehringer Ingelheim International GmbH Somatostatin Analogue Drug Introduction
11.14.4 Boehringer Ingelheim International GmbH Revenue in Somatostatin Analogue Drug Business (2020-2025)
11.14.5 Boehringer Ingelheim International GmbH Recent Development
11.15 Eli Lilly & Co.
11.15.1 Eli Lilly & Co. Company Details
11.15.2 Eli Lilly & Co. Business Overview
11.15.3 Eli Lilly & Co. Somatostatin Analogue Drug Introduction
11.15.4 Eli Lilly & Co. Revenue in Somatostatin Analogue Drug Business (2020-2025)
11.15.5 Eli Lilly & Co. Recent Development
11.16 F. Hoffmann-La Roche Ltd.
11.16.1 F. Hoffmann-La Roche Ltd. Company Details
11.16.2 F. Hoffmann-La Roche Ltd. Business Overview
11.16.3 F. Hoffmann-La Roche Ltd. Somatostatin Analogue Drug Introduction
11.16.4 F. Hoffmann-La Roche Ltd. Revenue in Somatostatin Analogue Drug Business (2020-2025)
11.16.5 F. Hoffmann-La Roche Ltd. Recent Development
11.17 Novartis AG
11.17.1 Novartis AG Company Details
11.17.2 Novartis AG Business Overview
11.17.3 Novartis AG Somatostatin Analogue Drug Introduction
11.17.4 Novartis AG Revenue in Somatostatin Analogue Drug Business (2020-2025)
11.17.5 Novartis AG Recent Development
11.18 Pfizer Inc.
11.18.1 Pfizer Inc. Company Details
11.18.2 Pfizer Inc. Business Overview
11.18.3 Pfizer Inc. Somatostatin Analogue Drug Introduction
11.18.4 Pfizer Inc. Revenue in Somatostatin Analogue Drug Business (2020-2025)
11.18.5 Pfizer Inc. Recent Development
11.19 Tarveda Therapeutics Inc.
11.19.1 Tarveda Therapeutics Inc. Company Details
11.19.2 Tarveda Therapeutics Inc. Business Overview
11.19.3 Tarveda Therapeutics Inc. Somatostatin Analogue Drug Introduction
11.19.4 Tarveda Therapeutics Inc. Revenue in Somatostatin Analogue Drug Business (2020-2025)
11.19.5 Tarveda Therapeutics Inc. Recent Development
11.20 Teva Pharmaceutical Industries Ltd.
11.20.1 Teva Pharmaceutical Industries Ltd. Company Details
11.20.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.20.3 Teva Pharmaceutical Industries Ltd. Somatostatin Analogue Drug Introduction
11.20.4 Teva Pharmaceutical Industries Ltd. Revenue in Somatostatin Analogue Drug Business (2020-2025)
11.20.5 Teva Pharmaceutical Industries Ltd. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Camurus AB
Chiasma Inc
Ipsen Group
Boehringer Ingelheim International GmbH
Eli Lilly & Co
F Hoffmann La Roche Ltd
Novartis
Pfizer Inc
Tarveda Therapeutics Inc
Teva Pharmaceutical Industries Ltd
List of Tables
 Table 1. Global Somatostatin Analogue Drug Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Octreotide
 Table 3. Key Players of Lanreotide
 Table 4. Key Players of Pasireotide
 Table 5. Key Players of Octreotide
 Table 6. Key Players of Lanreotide
 Table 7. Key Players of Pasireotide
 Table 8. Global Somatostatin Analogue Drug Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 9. Global Somatostatin Analogue Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 10. Global Somatostatin Analogue Drug Market Size by Region (2020-2025) & (US$ Million)
 Table 11. Global Somatostatin Analogue Drug Market Share by Region (2020-2025)
 Table 12. Global Somatostatin Analogue Drug Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 13. Global Somatostatin Analogue Drug Market Share by Region (2026-2031)
 Table 14. Somatostatin Analogue Drug Market Trends
 Table 15. Somatostatin Analogue Drug Market Drivers
 Table 16. Somatostatin Analogue Drug Market Challenges
 Table 17. Somatostatin Analogue Drug Market Restraints
 Table 18. Global Somatostatin Analogue Drug Revenue by Players (2020-2025) & (US$ Million)
 Table 19. Global Somatostatin Analogue Drug Market Share by Players (2020-2025)
 Table 20. Global Top Somatostatin Analogue Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Somatostatin Analogue Drug as of 2024)
 Table 21. Ranking of Global Top Somatostatin Analogue Drug Companies by Revenue (US$ Million) in 2024
 Table 22. Global 5 Largest Players Market Share by Somatostatin Analogue Drug Revenue (CR5 and HHI) & (2020-2025)
 Table 23. Global Key Players of Somatostatin Analogue Drug, Headquarters and Area Served
 Table 24. Global Key Players of Somatostatin Analogue Drug, Product and Application
 Table 25. Global Key Players of Somatostatin Analogue Drug, Date of Enter into This Industry
 Table 26. Mergers & Acquisitions, Expansion Plans
 Table 27. Global Somatostatin Analogue Drug Market Size by Type (2020-2025) & (US$ Million)
 Table 28. Global Somatostatin Analogue Drug Revenue Market Share by Type (2020-2025)
 Table 29. Global Somatostatin Analogue Drug Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 30. Global Somatostatin Analogue Drug Revenue Market Share by Type (2026-2031)
 Table 31. Global Somatostatin Analogue Drug Market Size by Application (2020-2025) & (US$ Million)
 Table 32. Global Somatostatin Analogue Drug Revenue Market Share by Application (2020-2025)
 Table 33. Global Somatostatin Analogue Drug Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 34. Global Somatostatin Analogue Drug Revenue Market Share by Application (2026-2031)
 Table 35. North America Somatostatin Analogue Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 36. North America Somatostatin Analogue Drug Market Size by Country (2020-2025) & (US$ Million)
 Table 37. North America Somatostatin Analogue Drug Market Size by Country (2026-2031) & (US$ Million)
 Table 38. Europe Somatostatin Analogue Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 39. Europe Somatostatin Analogue Drug Market Size by Country (2020-2025) & (US$ Million)
 Table 40. Europe Somatostatin Analogue Drug Market Size by Country (2026-2031) & (US$ Million)
 Table 41. Asia-Pacific Somatostatin Analogue Drug Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 42. Asia-Pacific Somatostatin Analogue Drug Market Size by Region (2020-2025) & (US$ Million)
 Table 43. Asia-Pacific Somatostatin Analogue Drug Market Size by Region (2026-2031) & (US$ Million)
 Table 44. Latin America Somatostatin Analogue Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 45. Latin America Somatostatin Analogue Drug Market Size by Country (2020-2025) & (US$ Million)
 Table 46. Latin America Somatostatin Analogue Drug Market Size by Country (2026-2031) & (US$ Million)
 Table 47. Middle East & Africa Somatostatin Analogue Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 48. Middle East & Africa Somatostatin Analogue Drug Market Size by Country (2020-2025) & (US$ Million)
 Table 49. Middle East & Africa Somatostatin Analogue Drug Market Size by Country (2026-2031) & (US$ Million)
 Table 50. Camurus AB Company Details
 Table 51. Camurus AB Business Overview
 Table 52. Camurus AB Somatostatin Analogue Drug Product
 Table 53. Camurus AB Revenue in Somatostatin Analogue Drug Business (2020-2025) & (US$ Million)
 Table 54. Camurus AB Recent Development
 Table 55. Chiasma Company Details
 Table 56. Chiasma Business Overview
 Table 57. Chiasma Somatostatin Analogue Drug Product
 Table 58. Chiasma Revenue in Somatostatin Analogue Drug Business (2020-2025) & (US$ Million)
 Table 59. Chiasma Recent Development
 Table 60. Ipsen Group Company Details
 Table 61. Ipsen Group Business Overview
 Table 62. Ipsen Group Somatostatin Analogue Drug Product
 Table 63. Ipsen Group Revenue in Somatostatin Analogue Drug Business (2020-2025) & (US$ Million)
 Table 64. Ipsen Group Recent Development
 Table 65. Boehringer Ingelheim International GmbH Company Details
 Table 66. Boehringer Ingelheim International GmbH Business Overview
 Table 67. Boehringer Ingelheim International GmbH Somatostatin Analogue Drug Product
 Table 68. Boehringer Ingelheim International GmbH Revenue in Somatostatin Analogue Drug Business (2020-2025) & (US$ Million)
 Table 69. Boehringer Ingelheim International GmbH Recent Development
 Table 70. Eli Lilly & Co. Company Details
 Table 71. Eli Lilly & Co. Business Overview
 Table 72. Eli Lilly & Co. Somatostatin Analogue Drug Product
 Table 73. Eli Lilly & Co. Revenue in Somatostatin Analogue Drug Business (2020-2025) & (US$ Million)
 Table 74. Eli Lilly & Co. Recent Development
 Table 75. F. Hoffmann-La Roche Ltd. Company Details
 Table 76. F. Hoffmann-La Roche Ltd. Business Overview
 Table 77. F. Hoffmann-La Roche Ltd. Somatostatin Analogue Drug Product
 Table 78. F. Hoffmann-La Roche Ltd. Revenue in Somatostatin Analogue Drug Business (2020-2025) & (US$ Million)
 Table 79. F. Hoffmann-La Roche Ltd. Recent Development
 Table 80. Novartis AG Company Details
 Table 81. Novartis AG Business Overview
 Table 82. Novartis AG Somatostatin Analogue Drug Product
 Table 83. Novartis AG Revenue in Somatostatin Analogue Drug Business (2020-2025) & (US$ Million)
 Table 84. Novartis AG Recent Development
 Table 85. Pfizer Inc. Company Details
 Table 86. Pfizer Inc. Business Overview
 Table 87. Pfizer Inc. Somatostatin Analogue Drug Product
 Table 88. Pfizer Inc. Revenue in Somatostatin Analogue Drug Business (2020-2025) & (US$ Million)
 Table 89. Pfizer Inc. Recent Development
 Table 90. Tarveda Therapeutics Inc. Company Details
 Table 91. Tarveda Therapeutics Inc. Business Overview
 Table 92. Tarveda Therapeutics Inc. Somatostatin Analogue Drug Product
 Table 93. Tarveda Therapeutics Inc. Revenue in Somatostatin Analogue Drug Business (2020-2025) & (US$ Million)
 Table 94. Tarveda Therapeutics Inc. Recent Development
 Table 95. Teva Pharmaceutical Industries Ltd. Company Details
 Table 96. Teva Pharmaceutical Industries Ltd. Business Overview
 Table 97. Teva Pharmaceutical Industries Ltd. Somatostatin Analogue Drug Product
 Table 98. Teva Pharmaceutical Industries Ltd. Revenue in Somatostatin Analogue Drug Business (2020-2025) & (US$ Million)
 Table 99. Teva Pharmaceutical Industries Ltd. Recent Development
 Table 100. Camurus AB Company Details
 Table 101. Camurus AB Business Overview
 Table 102. Camurus AB Somatostatin Analogue Drug Product
 Table 103. Camurus AB Revenue in Somatostatin Analogue Drug Business (2020-2025) & (US$ Million)
 Table 104. Camurus AB Recent Development
 Table 105. Chiasma Company Details
 Table 106. Chiasma Business Overview
 Table 107. Chiasma Somatostatin Analogue Drug Product
 Table 108. Chiasma Revenue in Somatostatin Analogue Drug Business (2020-2025) & (US$ Million)
 Table 109. Chiasma Recent Development
 Table 110. Ipsen Group Company Details
 Table 111. Ipsen Group Business Overview
 Table 112. Ipsen Group Somatostatin Analogue Drug Product
 Table 113. Ipsen Group Revenue in Somatostatin Analogue Drug Business (2020-2025) & (US$ Million)
 Table 114. Ipsen Group Recent Development
 Table 115. Boehringer Ingelheim International GmbH Company Details
 Table 116. Boehringer Ingelheim International GmbH Business Overview
 Table 117. Boehringer Ingelheim International GmbH Somatostatin Analogue Drug Product
 Table 118. Boehringer Ingelheim International GmbH Revenue in Somatostatin Analogue Drug Business (2020-2025) & (US$ Million)
 Table 119. Boehringer Ingelheim International GmbH Recent Development
 Table 120. Eli Lilly & Co. Company Details
 Table 121. Eli Lilly & Co. Business Overview
 Table 122. Eli Lilly & Co. Somatostatin Analogue Drug Product
 Table 123. Eli Lilly & Co. Revenue in Somatostatin Analogue Drug Business (2020-2025) & (US$ Million)
 Table 124. Eli Lilly & Co. Recent Development
 Table 125. F. Hoffmann-La Roche Ltd. Company Details
 Table 126. F. Hoffmann-La Roche Ltd. Business Overview
 Table 127. F. Hoffmann-La Roche Ltd. Somatostatin Analogue Drug Product
 Table 128. F. Hoffmann-La Roche Ltd. Revenue in Somatostatin Analogue Drug Business (2020-2025) & (US$ Million)
 Table 129. F. Hoffmann-La Roche Ltd. Recent Development
 Table 130. Novartis AG Company Details
 Table 131. Novartis AG Business Overview
 Table 132. Novartis AG Somatostatin Analogue Drug Product
 Table 133. Novartis AG Revenue in Somatostatin Analogue Drug Business (2020-2025) & (US$ Million)
 Table 134. Novartis AG Recent Development
 Table 135. Pfizer Inc. Company Details
 Table 136. Pfizer Inc. Business Overview
 Table 137. Pfizer Inc. Somatostatin Analogue Drug Product
 Table 138. Pfizer Inc. Revenue in Somatostatin Analogue Drug Business (2020-2025) & (US$ Million)
 Table 139. Pfizer Inc. Recent Development
 Table 140. Tarveda Therapeutics Inc. Company Details
 Table 141. Tarveda Therapeutics Inc. Business Overview
 Table 142. Tarveda Therapeutics Inc. Somatostatin Analogue Drug Product
 Table 143. Tarveda Therapeutics Inc. Revenue in Somatostatin Analogue Drug Business (2020-2025) & (US$ Million)
 Table 144. Tarveda Therapeutics Inc. Recent Development
 Table 145. Teva Pharmaceutical Industries Ltd. Company Details
 Table 146. Teva Pharmaceutical Industries Ltd. Business Overview
 Table 147. Teva Pharmaceutical Industries Ltd. Somatostatin Analogue Drug Product
 Table 148. Teva Pharmaceutical Industries Ltd. Revenue in Somatostatin Analogue Drug Business (2020-2025) & (US$ Million)
 Table 149. Teva Pharmaceutical Industries Ltd. Recent Development
 Table 150. Research Programs/Design for This Report
 Table 151. Key Data Information from Secondary Sources
 Table 152. Key Data Information from Primary Sources
 Table 153. Authors List of This Report


List of Figures
 Figure 1. Somatostatin Analogue Drug Picture
 Figure 2. Global Somatostatin Analogue Drug Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Somatostatin Analogue Drug Market Share by Type: 2024 VS 2031
 Figure 4. Octreotide Features
 Figure 5. Lanreotide Features
 Figure 6. Pasireotide Features
 Figure 7. Octreotide Features
 Figure 8. Lanreotide Features
 Figure 9. Pasireotide Features
 Figure 10. Global Somatostatin Analogue Drug Market Size by Application (2020-2031) & (US$ Million)
 Figure 11. Global Somatostatin Analogue Drug Market Share by Application: 2024 VS 2031
 Figure 12. Acromegaly Case Studies
 Figure 13. Neuroendocrine Tumor (NET) Case Studies
 Figure 14. Others Case Studies
 Figure 15. Acromegaly Case Studies
 Figure 16. Neuroendocrine Tumor (NET) Case Studies
 Figure 17. Others Case Studies
 Figure 18. Somatostatin Analogue Drug Report Years Considered
 Figure 19. Global Somatostatin Analogue Drug Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 20. Global Somatostatin Analogue Drug Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 21. Global Somatostatin Analogue Drug Market Share by Region: 2024 VS 2031
 Figure 22. Global Somatostatin Analogue Drug Market Share by Players in 2024
 Figure 23. Global Top Somatostatin Analogue Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Somatostatin Analogue Drug as of 2024)
 Figure 24. The Top 10 and 5 Players Market Share by Somatostatin Analogue Drug Revenue in 2024
 Figure 25. North America Somatostatin Analogue Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. North America Somatostatin Analogue Drug Market Share by Country (2020-2031)
 Figure 27. United States Somatostatin Analogue Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. Canada Somatostatin Analogue Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Europe Somatostatin Analogue Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Europe Somatostatin Analogue Drug Market Share by Country (2020-2031)
 Figure 31. Germany Somatostatin Analogue Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. France Somatostatin Analogue Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. U.K. Somatostatin Analogue Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Italy Somatostatin Analogue Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. Russia Somatostatin Analogue Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. Nordic Countries Somatostatin Analogue Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Asia-Pacific Somatostatin Analogue Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Asia-Pacific Somatostatin Analogue Drug Market Share by Region (2020-2031)
 Figure 39. China Somatostatin Analogue Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Japan Somatostatin Analogue Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. South Korea Somatostatin Analogue Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Southeast Asia Somatostatin Analogue Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. India Somatostatin Analogue Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Australia Somatostatin Analogue Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Latin America Somatostatin Analogue Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Latin America Somatostatin Analogue Drug Market Share by Country (2020-2031)
 Figure 47. Mexico Somatostatin Analogue Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. Brazil Somatostatin Analogue Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 49. Middle East & Africa Somatostatin Analogue Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 50. Middle East & Africa Somatostatin Analogue Drug Market Share by Country (2020-2031)
 Figure 51. Turkey Somatostatin Analogue Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 52. Saudi Arabia Somatostatin Analogue Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 53. UAE Somatostatin Analogue Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 54. Camurus AB Revenue Growth Rate in Somatostatin Analogue Drug Business (2020-2025)
 Figure 55. Chiasma Revenue Growth Rate in Somatostatin Analogue Drug Business (2020-2025)
 Figure 56. Ipsen Group Revenue Growth Rate in Somatostatin Analogue Drug Business (2020-2025)
 Figure 57. Boehringer Ingelheim International GmbH Revenue Growth Rate in Somatostatin Analogue Drug Business (2020-2025)
 Figure 58. Eli Lilly & Co. Revenue Growth Rate in Somatostatin Analogue Drug Business (2020-2025)
 Figure 59. F. Hoffmann-La Roche Ltd. Revenue Growth Rate in Somatostatin Analogue Drug Business (2020-2025)
 Figure 60. Novartis AG Revenue Growth Rate in Somatostatin Analogue Drug Business (2020-2025)
 Figure 61. Pfizer Inc. Revenue Growth Rate in Somatostatin Analogue Drug Business (2020-2025)
 Figure 62. Tarveda Therapeutics Inc. Revenue Growth Rate in Somatostatin Analogue Drug Business (2020-2025)
 Figure 63. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Somatostatin Analogue Drug Business (2020-2025)
 Figure 64. Camurus AB Revenue Growth Rate in Somatostatin Analogue Drug Business (2020-2025)
 Figure 65. Chiasma Revenue Growth Rate in Somatostatin Analogue Drug Business (2020-2025)
 Figure 66. Ipsen Group Revenue Growth Rate in Somatostatin Analogue Drug Business (2020-2025)
 Figure 67. Boehringer Ingelheim International GmbH Revenue Growth Rate in Somatostatin Analogue Drug Business (2020-2025)
 Figure 68. Eli Lilly & Co. Revenue Growth Rate in Somatostatin Analogue Drug Business (2020-2025)
 Figure 69. F. Hoffmann-La Roche Ltd. Revenue Growth Rate in Somatostatin Analogue Drug Business (2020-2025)
 Figure 70. Novartis AG Revenue Growth Rate in Somatostatin Analogue Drug Business (2020-2025)
 Figure 71. Pfizer Inc. Revenue Growth Rate in Somatostatin Analogue Drug Business (2020-2025)
 Figure 72. Tarveda Therapeutics Inc. Revenue Growth Rate in Somatostatin Analogue Drug Business (2020-2025)
 Figure 73. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Somatostatin Analogue Drug Business (2020-2025)
 Figure 74. Bottom-up and Top-down Approaches for This Report
 Figure 75. Data Triangulation
 Figure 76. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Accenture

SIMILAR REPORTS

Global Octreotide Drugs Market Research Report 2024
Somatostatin and Somatostatin Analogs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Somatostatin Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Manmade Version of Somatostatin Market Research Report 2024
Lanreotide Injection Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Growth Hormone inhibiting Hormone Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Octreotide Sales Market Report Competitive Analysis and Regional Opportunities 2025 2031
Somatuline Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Somatostatin Sales Market Report Competitive Analysis and Regional Opportunities 2025 2031
Sandostatin LAR Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Somatuline Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Lanreotide Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Sandostatin LAR Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Lanreotide Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Somatostatin for Injection Market Research Report 2024
Global Long acting Somatostatin Analogues LA SSAs Market Research Report 2024
Global Neuroendocrine Tumors NETs Treatment Market Insights Forecast to 2030
Acromegaly Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Neuroendocrine Tumor Treatment Market Insights Forecast to 2030
GLP 1 Analogues Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions